<p>Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines</p>

Abstract

PurposeTo investigate the IOP lowering effect and safety of tafluprost 0.0015% in a routine clinical setting in the Philippines.Patients and methodsA retrospective review of glaucoma patients receiving tafluprost 0.0015% (BAK 0.001% preserved) with a minimum follow-up of 3 months was conducted. Main outcome measure was the mean IOP change at month 3. Secondary outcome measures included longitudinal IOP assessments and occurrence of any adverse events.ResultsThree-hundred twenty-nine eyes of 177 patients with mean age 64.8 years were included and followed for mean 8.8 months. Most common diagnosis was primary open-angle glaucoma (POAG) (34.9%), followed by primary angle-closure (PAC) glaucoma post-laser iridotomy (24.0%), PAC post-laser iridotomy (15.5%), ocular hypertension (OHT)(14.6%), secondary glaucoma (6.7%), and normal-tension glaucoma (4.3%). Mean IOP change at month 3 was −6.18 mmHg (SD 4.06), a −26.37% reduction (p<0.001) and IOP reduction was sustained throughout the study period (p<0.001). Sub-group analysis of treatment naïve (n=203); add-on (n=53) and replacement therapy (n=73) showed a 3-month mean IOP reduction of −8.34 mmHg (SD 2.57, p<0.001) or –31.24%, −5.08 mmHg (SD 2.86, p<0.001) or –23.68%, and −1.00 mmHg (SD 3.08; p=0.007) or –6.31%, respectively. There was significant IOP reduction from baseline in both POAG/OHT sub-group and the PAC/PACG post-laser iridotomy with ≥90° open-angle sub-group (p<0.001), sustained up to month 12 post-treatment. However, there was no significant difference in the average absolute (mmHg) or proportional IOP change from baseline between the two sub-groups. Conjunctival hyperemia was the most common adverse reaction occurring in 15% of patients.ConclusionTafluprost was a safe and effective IOP-lowering treatment in this routine clinical setting.

<p>Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients</p>

“…A recent retrospective study has reported that tafluprost was safe and showed the effective IOP lowering, which was sustained up to 12 months post-treatment. 41 The previous studies also showed that preserved PF-tafluprost significantly decreased the symptoms and signs of OSD when compared to latanoprost. 11,22 The result of this current study was similar to these previous studies reported.…”

Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience

“…A retrospective study of patients treated with tafluprost 0.0015% in a routine clinical setting in the Philippines, which included 329 eyes in 177 patients, found that the majority of patients (≥85%) reported no adverse effects over a mean follow-up period of 8.8 months. The rates of eye redness and conjunctival hyperemia were 10% and 15%, respectively [ 21 ]. No patients discontinued treatment due to adverse symptoms or signs during the study.…”

Ocular surface conditions in Asian glaucoma patients with existing corneal disorders switching from preserved prostaglandin analogue monotherapy to preservative-free tafluprost

“…Previous switch studies conducted on Asian eyes have been retrospective studies looking at varying glaucoma diagnoses, or prospective studies involving patients switched from different classes of medications or from a specific eyedrop only. 20,21 This study has the advantage of being a prospective study specifically evaluating POAG and OH patients switching from preserved PGA class to PF tafluprost in a multiethnic Asian population. Even though most glaucoma patients can tolerate preserved PGAs, a large number of patients do suffer from OSD caused by preservatives, specifically BAK.…”